Jounce Therapeutics, Inc. (JNCE) Social Stream



Jounce Therapeutics, Inc. (JNCE): $4.68

0.16 (+3.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add JNCE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Featured Post From StockTwits About JNCE

$JNCE Pipeline Update:
Monotherapy dose escalation portion of the Phase 1 trial of JTX-8064 is complete. The monotherapy dose ranging from 50 mg to 1200 mg. To date, JTX-8064 has been well-tolerated with no dose limiting toxicities. For the next stages of INNATE Jounce announces today the selection of its target dose of 700 mg.
BioOption, published August 5, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4774 seconds.